- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06284317
Een internationale, multicentrische, open-label gerandomiseerde fase III-studie om het voordeel te evalueren van het toevoegen van adjuvante durvalumab na neoadjuvante chemotherapie plus durvalumab bij patiënten met stadium IIB-IIIB (N2) reseceerbaar NSCLC (ADOPT-lung)
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery. Patients with R0 and R1 only resection will be randomised to receive either adjuvant durvalumab for 12 cycles (experimental arm) or observation (control arm). The primary objective of the study is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant chemo-immunotherapy has an effect on disease-free survival (DFS) in patients who do not achieve complete pathological response (pCR) as per local assessment according to the IASLC recommendations.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Heidi Roschitzki, PhD
- Telefoonnummer: +41 31 511 94 00
- E-mail: heidi.roschitzki@etop.ibcsg.org
Studie Contact Back-up
- Naam: Susanne Roux
- Telefoonnummer: +41 31 511 94 00
- E-mail: ADOPT-lung@etop.ibcsg.org
Studie Locaties
-
-
New South Wales
-
Camperdown, New South Wales, Australië
- Nog niet aan het werven
- Chris O'Brien Lifehouse
-
Contact:
- Malinda Itchins
-
Penrith, New South Wales, Australië
- Werving
- Nepean Hospital
-
Contact:
- Deme Karikios
-
St Leonards, New South Wales, Australië
- Werving
- Royal North Shore Hospital
-
Contact:
- Malinda Itchins
-
-
Queensland
-
Woolloongabba, Queensland, Australië
- Nog niet aan het werven
- Princess Alexandra Hospital
-
Contact:
- Kenneth O'Bryne
-
-
South Australia
-
Bedford Park, South Australia, Australië
- Nog niet aan het werven
- Flinders Medical Centre
-
Contact:
- Chris Karapetis
-
-
Tasmania
-
Hobart, Tasmania, Australië
- Nog niet aan het werven
- Royal Hobart Hospital
-
Contact:
- Rebecca Tay
-
-
Victoria
-
Box Hill, Victoria, Australië
- Werving
- Eastern Health
-
Contact:
- Phillip Parente
-
Melbourne, Victoria, Australië
- Werving
- Alfred Hospital
-
Contact:
- Maggie Moore
-
Parkville, Victoria, Australië
- Werving
- Peter MacCallum Cancer Centre
-
Contact:
- Benjamin Solomon
-
-
Western Australia
-
Nedlands, Western Australia, Australië
- Nog niet aan het werven
- Sir Charles Gairdner Hospital
-
Contact:
- Samantha Bowyer
-
-
-
-
-
Anderlecht, België
- Werving
- Institut Jules Bordet - HUB
-
Contact:
- Mariana Brandao
- E-mail: mariana.brandao@hubruxelles.be
-
Antwerp, België
- Werving
- Antwerp University Hospital
-
Contact:
- Reinier Wener
-
-
-
-
-
Talinn, Estland
- Werving
- North Estonia Medical Centre Foundation
-
Contact:
- Kersti Oselin
- E-mail: Kersti.Oselin@regionaalhaigla.ee
-
-
-
-
-
Angers, Frankrijk
- Werving
- CHU Angers
-
Contact:
- Youssef Oulkhouir
- E-mail: Youssef.Oulkhouir@chu-angers.fr
-
Bordeaux, Frankrijk
- Werving
- Institut Bergonié
-
Contact:
- Sophie Cousin
- E-mail: s.cousin@bordeaux.unicancer.fr
-
Le Mans, Frankrijk
- Werving
- Le Mans - CHG
-
Contact:
- Camille Guguen
- E-mail: cguguen@ch-lemans.fr
-
Lyon, Frankrijk
- Werving
- Lyon - Centre Léon Bérard
-
Contact:
- Maurice Pérol
- E-mail: maurice.perol@lyon.unicancer.fr
-
Metz, Frankrijk
- Werving
- Hôpital Robert Schuman - Groupe UNEOS
-
Contact:
- Lucile Roussel
-
-
-
-
-
Dublin, Ierland
- Werving
- Beaumont Hospital
-
Contact:
- Jarushka Naidoo
- E-mail: jarushkanaidoo@beaumont.ie
-
Dublin, Ierland
- Werving
- St James's Hospital
-
Contact:
- Patrick Forde
- E-mail: pforde1@jhmi.edu
-
-
-
-
-
Alessandria, Italië
- Nog niet aan het werven
- SS Antonio e Biagio e Cesare Arrigo Hospital
-
Contact:
- Pier Luigi Piovano
- E-mail: plpiovano@ospedale.al.it
-
Padova, Italië
- Werving
- Istituto Oncologico Veneto
-
Contact:
- Laura Bonnano
- E-mail: laura.bonanno@iov.veneto.it
-
Perugia, Italië
- Nog niet aan het werven
- Perugia Hospital
-
Contact:
- Giulio Metro
- E-mail: giulio.metro@ospedale.perugia.it
-
Rome, Italië
- Werving
- Istituto Nazionale Tumori "Regina Elena"
-
Contact:
- Landi Lorenza
- E-mail: lorenza.landi@ifo.it
-
Siena, Italië
- Nog niet aan het werven
- AOUS Policlinico Le Scotte
-
Contact:
- Michele Maio
- E-mail: mmaiocro@gmail.com
-
Verona, Italië
- Werving
- Universita di Verona - Department of Medicine
-
Contact:
- Lorenzo Belluomini
- E-mail: lorenzo.belluomini@univr.it
-
-
-
-
-
Amsterdam, Nederland
- Werving
- NKI
-
Contact:
- Willemijn Theelen
- E-mail: w.theelen@nki.nl
-
Utrecht, Nederland
- Werving
- UMCU
-
Contact:
- W.K. de Jong
- E-mail: w.k.dejong-9@umcutrecht.nl
-
-
-
-
-
Vienna, Oostenrijk
- Werving
- Wien AKH
-
Contact:
- Clemens Aigner
- E-mail: clemens.aigner@meduniwien.ac.at
-
-
-
-
-
Cardiff, Verenigd Koninkrijk
- Werving
- Velindre University NHS Trust
-
Contact:
- Paul Shaw
-
Glasgow, Verenigd Koninkrijk
- Nog niet aan het werven
- Beatson West of Scotland Cancer Centre NHS Greater Glasgow and Clyde
-
Contact:
- Nicola Steele
-
London, Verenigd Koninkrijk
- Werving
- Barts Health NHS Trust
-
Contact:
- Adam Januszewski
- E-mail: adam.januszewski@nhs.net
-
London, Verenigd Koninkrijk
- Nog niet aan het werven
- Royal Marsden Hospital (Chelsea)
-
Contact:
- Sanjay Popat
- E-mail: sanjay.popat@rmh.nhs.uk
-
London, Verenigd Koninkrijk
- Nog niet aan het werven
- Royal Marsden Hospital (Sutton)
-
Contact:
- Sanjay Popat
- E-mail: sanjay.popat@rmh.nhs.uk
-
Maidstone, Verenigd Koninkrijk
- Werving
- Maidstone and Tunbridge Wells NHS Trust
-
Contact:
- Riyaz Shah
- E-mail: riyaz.shah@nhs.net
-
Manchester, Verenigd Koninkrijk
- Werving
- Wythenshawe Hospital, Manchester University NHS Foundation Trust
-
Contact:
- Igor Randulfe
- E-mail: yvonne.summers@nhs.net
-
-
-
-
-
Baden, Zwitserland
- Nog niet aan het werven
- Kantonsspital Baden
-
Contact:
- Sacha Rothschild
- E-mail: sacha.rothschild@ksb.ch
-
Basel, Zwitserland
- Werving
- Universitätsspital Basel
-
Contact:
- David König
- E-mail: david.koenig@usb.ch
-
Bellinzona, Zwitserland
- Nog niet aan het werven
- Eoc - Iosi
-
Contact:
- Martina Imbimbo
- E-mail: martina.imbimbo@eoc.ch
-
Bern, Zwitserland
- Werving
- Inselspital Bern
-
Contact:
- Sabine Schmid
- E-mail: sabine.schmid@insel.ch
-
Fribourg, Zwitserland
- Werving
- HFR Hôpital Fribourgeois
-
Contact:
- Adrienne Bettini
- E-mail: Adrienne.Bettini@h-fr.ch
-
Lausanne, Zwitserland
- Nog niet aan het werven
- CHUV
-
Contact:
- Hasna Bouchaab
- E-mail: hasna.bouchaab@chuv.ch
-
Sankt Gallen, Zwitserland
- Werving
- Kantonsspital St.Gallen
-
Contact:
- Martin Früh
- E-mail: Martin.frueh@kssg.ch
-
Winterthur, Zwitserland
- Werving
- Kantonsspital Winterthur
-
Contact:
- Laetitia Mauti
- E-mail: laetitia.mauti@ksw.ch
-
Zurich, Zwitserland
- Nog niet aan het werven
- University Hospital Zurich
-
Contact:
- Isabelle Opitz
- E-mail: isabelle.schmitt-opitz@usz.ch
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria for enrolment:
- Histologically confirmed NSCLC.
- Stage IIB-IIIB (T1-4 N0-2) according to 8th edition of the TNM staging system of lung cancer.
Stage III assessment should include samples of lymph nodes at levels 4, bilaterally, and level 7 to rule out stage IIIB N3 disease.
T4 tumours will only be eligible if they are defined as T4 based only on their size (>7cm); any other reason will be considered ineligible.
- Known PD-L1 status, as tested locally using a validated assay. To ensure comparability of results, it is strongly encouraged that PD-L1 testing is done with the Ventana PD-L1 (SP263) assay.
- Absence of EGFR mutation or ALK translocation, as tested locally.
- Primary tumour resectable and functionally operable as assessed per local multidisciplinary tumour board (cardiac evaluation, pulmonary function and diffusion capacity, comorbidity).
- Adequate haematological function:
Haemoglobin ≥90 g/L, Absolute neutrophil count (ANC) ≥1.0× 109/L, Platelet count ≥75× 109/L.
- Adequate renal function: Measured creatinine clearance (CL) >40 mL/min or calculated CL >40 mL/min calculated by the Cockcroft-Gault.
- Adequate liver function: ALT and AST ≤2.5× institutional ULN, Total serum bilirubin ≤1.5× institutional ULN (patients with Gilbert's syndrome may be allowed to be enrolled after consultation with the Medical Affairs Team at the ETOP IBCSG Partners Foundation.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Age ≥18 at the time of enrolment.
- Body weight >30 kg.
- Life expectancy of at least 12 weeks.
- Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test at screening before enrolment. Pregnancy test must be repeated within 3 days before the first dose of protocol treatment.
- Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
Eligibility Criteria for randomisation:
- Surgical resection must have been completed. Note: Participants who have had only had segmentectomy or wedge resections are not eligible for randomisation.
- Patients must have complete resection: R0 or R1 resection.
- Patients must be fit to receive adjuvant treatment with durvalumab.
- Patients must have no evidence of metastatic disease as assessed by CT scan.
- Documentation of pathological response as per local review must be available.
Exclusion Criteria for enrolment:
- T4 with invasion of heart, great vessels, carina, trachea, oesophagus, or spine.
- Any previous or concurrent treatments for NSCLC.
- Any previous immunotherapy.
- Major surgical procedure (as per investigators assessment) within 28 days before enrolment.
- History of allogenic organ transplantation.
- Active or prior documented autoimmune disease or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:
Patients with vitiligo or alopecia. Patients with type I diabetes. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
Any chronic skin condition that does not require systemic therapy. Patients without active disease in the last 5 years may be included but only after consultation with the Medical Affairs Team at the ETOP IBCSG Partners Foundation.
Patients with celiac disease controlled by diet alone.
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease (ILD), or serious chronic gastrointestinal conditions associated with diarrhoea.
- Psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
- History of another primary malignancy except for:
Malignancy treated with curative-intent and with no known active disease 5 years before the first dose of durvalumab and of low potential risk for recurrence.
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
Adequately treated carcinoma in situ without evidence of disease.
- History of leptomeningeal carcinomatosis.
- History of active primary immunodeficiency.
- Active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HbsAg) or HBV core antibody (anti-HBc).
Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HbsAg) are eligible.
Participants positive for HCV antibody are only eligible if polymerase chain reaction is negative for HCV RNA.
- Known HIV infection that is not well-controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load for 3 months, CD4+ count of 500 cell per mm3, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 3 months on the same anti-HIV medication.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection).
Systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or its equivalent.
Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab.
Note: Patients in the ADOPT-lung trial, should not receive live vaccine whilst receiving durvalumab and for up to 30 days after the last dose.
Concurrent enrolment in another interventional clinical trial.
- Known allergy or suspected hypersensitivity to durvalumab or its excipients.
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
- Female patients who are pregnant or in the period of lactation.
- Female patients of childbearing potential and sexually active men who are not willing to use a highly effective contraceptive method during the trial until at least 90 days after the last dose of protocol treatment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Durvalumab
Protocol treatment in the adjuvant phase consists of adjuvant durvalumab |
Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery. |
|
Geen tussenkomst: Observation
Observation only |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Disease-free survival (DFS)
Tijdsspanne: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase. DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). DFS will be assessed in patients without pCR (primary endpoint), as well as in patients with pCR (secondary endpoint) and in patients with/without ctDNA clearance (secondary endpoints). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
DFS in patients with pCR
Tijdsspanne: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). DFS will be assessed in patients without pCR (primary endpoint), as well as in patients with pCR (secondary endpoint) and in patients with/without ctDNA clearance (secondary endpoints). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Overall survival (OS) in patients with/without pCR
Tijdsspanne: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). OS is defined as the time from the date of randomisation until death from any cause. Censoring (for patients who are not reported as having died) will occur at the date when they were last known to be alive. Patients without post-randomisation information will be censored at the date of randomisation (plus 1 day). OS will be assessed in patients with/without pCR. |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
DFS in patients with/without ctDNA clearance
Tijdsspanne: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Time to recurrence (TTR) in patients with/without pCR
Tijdsspanne: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). TTR is defined as the time from the date of randomisation until disease recurrence. Censoring (for patients without recurrence) will occur at the date of the last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). TTR will be assessed in patients with/without pCR. |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Time to treatment discontinuation (TTD) in patients with/without pCR
Tijdsspanne: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Toxicity according to CTCAE v5.0
Tijdsspanne: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). All safety parameters will be summarised in tables to evaluate the toxicity/safety profile of the protocol treatment based on:
|
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Correlation between ctDNA clearance and DFS
Tijdsspanne: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Exploratory endpoint |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation between ctDNA clearance and OS
Tijdsspanne: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Exploratory endpoint |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation between ctDNA clearance and initial PD-L1 assessment
Tijdsspanne: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Exploratory endpoint |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Outcome (event-free survival)
Tijdsspanne: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Outcome (EFS) in patients with patients with either
|
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation of Outcome Disease-free survival (DFS)
Tijdsspanne: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Correlation of Outcome (DFS) in patients with longitudinal ctDNA assessment |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation of Outcome Overall survival (OS)
Tijdsspanne: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Correlation of Outcome (OS) in patients with longitudinal ctDNA assessment |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
pCRDescription of patients entering each phase (e.g., % surgery, % randomised)
Tijdsspanne: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
pCRDescription of patients entering each phase (e.g., % surgery, % randomised) |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie stoel: Solange Peters, MD-PhD, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
- Studie stoel: Sabine Schmid, MD, Inselspital, Universitätsspital Bern, 3010 Bern, Switzerland
- Studie stoel: Paul Van Schil, MD-PhD, Antwerp University Hospital, Antwerp, Belgium,
- Studie stoel: Stephen Finn, MD-PhD, St. James's Hospital, Dublin 8, Ireland
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ETOP 25-23
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .